AGP Executive Report
Last update: 2 hours agoWeight-Loss Drugs: Eli Lilly’s orforglipron became the first GLP-1 weight-loss pill approved in China, opening a new contest in a market analysts expect to grow rapidly. Cardiac Care: Asia-Pacific accounts for just 7.7% of enrolment in major heart, diabetes and obesity trials despite representing nearly 60% of the world’s population. Researchers warn that treatments tested mainly on Western patients may carry different risks for Asians. Regional Cooperation: BIMSTEC health ministers adopted a regional public-health statement, with India offering to share expertise; seven Asian nations also agreed to strengthen disease surveillance. Changing Expectations: A BCG survey found China and India lead healthcare consumerization among ten markets, as patients increasingly seek more choice, transparency and retail-like convenience. Pacific Resilience: A new ADB- and GCF-backed programme aims to mobilise more than US$1 billion to protect 14 Pacific economies from rising seas and storms, including by strengthening water and power systems. Covid Watch: The PJ.2.1 variant has spread to Asia, but early lab findings suggest antibodies from updated vaccines can still neutralise it.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
